Cell:研究将加快强效抗精神病药的研发

2011-12-14 MedSci原创 MedSci原创

近日,国家著名杂志《细胞》Cell上发表了西奈山医学院的研究人员的最新研究成果“Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs。”,研究人员发现抗精神病药在由两种精神分裂症相关性大脑受体组成的复合体中诱导的细胞信号传导

近日,国家著名杂志《细胞》Cell上发表了西奈山医学院的研究人员的最新研究成果“Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs。”,研究人员发现抗精神病药在由两种精神分裂症相关性大脑受体组成的复合体中诱导的细胞信号传导模式,该发现将促使研究人员预测新化合物治疗精神分裂症及其它严重精神障碍的疗效,可能会加快强效抗精神病药的研发。

至今,当前精神分裂症疗法达预期抗精神病疗效的分子机制不清。精神分裂症累及全球约1%的人群,是一种严重的慢性疾病,其特征有幻觉、妄想与认知缺陷。氯氮平是最有效的抗精神病药物,其最初研发用于抗抑郁,后经发现其具有抗精神病特征。然而,氯氮平的应用具有严重不良效应,如血糖异常与白细胞计数值低,严重限制了其应用。

在该研究中,由西奈山医学院精神病学与神经病学副教授Javier Gonzalez-Maeso博士与弗吉尼亚联邦大学生理学与生物物理学教授及系主任Diomedes Logothetis博士带领的研究团队探究了抗精神病药与致幻剂对两种与精神分裂症相关的脑受体(谷氨酸mGlu2受体与5-羟色胺5-HT2A受体)的效应。致幻剂用于诱导精神分裂症的一项主要症状。

抗精神病药显著增高谷氨酸受体活性水平,降低5-羟色胺受体活性水平。引入致幻剂具有相反效应。虽然不清楚理想比率,但健康大脑的谷氨酸受体活性水平较高、5-羟色胺受体活性水平较低,而精神分裂症患者的大脑中二者的平衡被颠倒。

该研究建立于同一团队进行的早期研究基础之上,后者发现这些谷氨酸与5-羟色胺受体相互交流并构成单个复合开关发挥作用。

“在研究前两期,我们在受体复合体如何形成、如何发送信号及药物如何改变该信号活动以治疗或引起精神病上已有重要发现,”该研究第一作者Miguel Fribourg博士说道,Miguel Fribourg在Stuart Sealfon博士的实验室读博士后,Stuart Sealfon是该研究的共同作者及西奈山医学院神经系Glickenhaus教授与系主任。

在接下来的研究中,研究人员将寻找可使这两种受体间获最佳平衡的疗法。

“既然我们知道当前药物是如何影响该谷氨酸-5-羟色胺受体复合体的活性比,可尝试寻找或研发促使信号比恢复正常的疗法,从而高效治疗精神分裂症,”Gonzalez-Maeso博士说。

该研究是西奈山医学院、弗吉尼亚联邦大学与马里兰大学药学院共同努力的结果。“这是一项基于团队的合作性研究典范,结合了从细胞分子生物学至计算生物物理学、神经化学及行为药理学的多学科方法,”西奈山结构与化学生物学副教授Marta Filizola博士说道。Filizola博士的团队通过计算机模拟有助于了解抗精神病药诱导谷氨酸-5-羟色胺信号通路的机制。(生物谷Bioon.com)

Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs

Miguel Fribourg, José L. Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K. Adney, Candice Hatcher, José M. Eltit, Jeffrey D. Ruta, Laura Albizu, Zheng Li, Adrienne Umali, Jihyun Shim, Alexandre Fabiato, Alexander D. MacKerell, Vladimir Brezina, Stuart C. Sealfon, Marta Filizola, Javier González-Maeso, Diomedes E.

Highlights Endogenous signals via 2AR/mGluR2 enhance Gi and reduce Gq signaling Atypical and glutamate antipsychotics promote high Gi to Gq activity Psychedelics signal via 2AR/mGluR2 to decrease the Gi to Gq difference The balance index explains the basis for combined antipsychotics therapy Summary Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT2A G protein-coupled receptor (GPCR), the 2AR, which signals via a Gq heterotrimeric G protein. The closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 2AR function, but they lack comparable neuropsychological effects. Why some but not all 2AR inhibitors exhibit antipsychotic properties remains unresolved. We now show that a heteromeric complex between the 2AR and the Gi-linked GPCR, metabotropic glutamate 2 receptor (mGluR2), integrates ligand input, modulating signaling output and behavioral changes. Serotonergic and glutamatergic drugs bind the mGluR2/2AR heterocomplex, which then balances Gi- and Gq-dependent signaling. We find that the mGluR2/2AR-mediated changes in Gi and Gq activity predict the psychoactive behavioral effects of a variety of pharmocological compounds. These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958653, encodeId=9e5f195865358, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 05 23:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868440, encodeId=b7af186844042, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 11 14:46:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299712, encodeId=8bf31299e1235, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513039, encodeId=da9315130390f, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=)]
    2012-08-05 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958653, encodeId=9e5f195865358, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 05 23:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868440, encodeId=b7af186844042, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 11 14:46:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299712, encodeId=8bf31299e1235, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513039, encodeId=da9315130390f, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958653, encodeId=9e5f195865358, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 05 23:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868440, encodeId=b7af186844042, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 11 14:46:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299712, encodeId=8bf31299e1235, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513039, encodeId=da9315130390f, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=)]
    2011-12-16 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958653, encodeId=9e5f195865358, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 05 23:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868440, encodeId=b7af186844042, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 11 14:46:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299712, encodeId=8bf31299e1235, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513039, encodeId=da9315130390f, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Fri Dec 16 10:46:00 CST 2011, time=2011-12-16, status=1, ipAttribution=)]

相关资讯

2010年度精神病学年度研究进展

作者:北京大学精神卫生研究所 于欣 来源:中国医学论坛报   精神病学作为一门相当年轻的临床学科,在过去100年中发展迅速。近20年来,随着神经科学的不断进步及社会对精神卫生的关注,精神病学更是有了突飞猛进的发展。   2010年1月,《自然》杂志主编菲利浦·坎贝尔(Philip Campbell)提议,将未来的10年定为“精神障碍的10年”。这并非指精神障碍在未来10年将出现大流行